ArticleFrontiers in immunology2017
Immunization with Live Attenuated
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine.Scientific reports · 2024Article
- Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis.Frontiers in immunology · 2024Review
- Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-AttenuatedMicroorganisms · 2023Review
- The History of Live AttenuatedPathogens (Basel, Switzerland) · 2022Review
- Expression analysis of centrin gene in promastigote and amastigote forms of leishmania infantum iranian isolates: a promising target for live attenuated vaccine development against canine leishmaniasis.BMC veterinary research · 2021Article
- Characterization of a new Leishmania major strain for use in a controlled human infection model.Nature communications · 2021Article
- Non-Coding RNAs in the Etiology and Control of Major and Neglected Human Tropical Diseases.Frontiers in immunology · 2021Review
- The potential impact of human visceral leishmaniasis vaccines on population incidence.PLoS neglected tropical diseases · 2020Article
- Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2020Review
- Review
- miR-21 Expression Determines the Early Vaccine Immunity Induced byFrontiers in immunology · 2019Article
- Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is no vaccine against visceral leishmaniasis (VL). Toward developing an effective vaccine, we have reported extensively on the immunogenicity of live attenuated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.